BioPharma Resources

Drug Trial Radar · NCT03288532

Renal Adjuvant MultiPle Arm Randomised Trial

An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse

Last checked: Nov 19, 2026Latest source record: Sep 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,750 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,750

Planned (sponsor's estimate)

Start

Jul 19, 2018

Primary completion

Jul 1, 2024

Study completion Dec 1, 2034

Sponsor

Lead sponsor
University College, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AstraZeneca; Kidney Cancer UK; Cancer Research UK
First posted
Sep 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: The current global standard of care after nephrectomy for localised RCC therefore remains active monitoring (i.e., observation by clinical and radiological means). 30-40% patients with initially localised RCC develop metastatic disease following nephrectomy. Need for adjuvant therapy is most marked in the high risk population where outcomes are predictably poor. However, the risk of recurrence in patients who are of intermediate risk of recurrence is not insignificant. Unfortunately, despite showing efficacy in advanced RCC, the results in the adjuvant setting, so far, are inconclusive. AIM: RAMPART is a phase III Multi-Arm Multi-Stage randomised controlled platform trial, initiated with three arms. The trial is assessing if durvalumab monotherapy or the combination of durvalumab and tremelimumab can improve Disease Free Survival (DFS) or Overall Survival (OS) compared to the current global standard-of-care (active monitoring). At the start of recruitment, patients with Leibovich scores 3 to 11 will be eligible for randomisation. Accrual of intermediate risk patients (Leibovich scores 3 5) will stop after 3 years or when intermediate risk patients contribute 25% of the total accrual target, whichever is earlier. Recruitment of patients with Leibovich scores 6 to 11 will continue until the accrual target is reached.

Conditions

  • Renal Cell Carcinoma

Interventions

  • DurvalumabDrug

    controlled infusion via an infusion pump into a peripheral or central vein

  • TremelimumabDrug

    controlled infusion via an infusion pump into a peripheral or central vein

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Free Survival (DFS): Arm C vs ATime frame: 6.25 years
  2. Disease Free Survival (DFS): Arm B vs ATime frame: 10.54 years
  3. Overall Survival (OS): Arm C vs A (high risk patients only)Time frame: 13.25 years
  4. Overall Survival (OS): Arm B vs A (high risk patients only)Time frame: 20.5 years

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Aberdeen Royal Infirmary

    Aberdeen, United Kingdom · Recruiting

  • Ysbyty Gwynedd

    Bangor, United Kingdom · Recruiting

  • Royal Bournemouth Hospital

    Bournemouth, United Kingdom · Recruiting

  • Bristol Haematology and Oncology Centre

    Bristol, United Kingdom · Recruiting

  • Addenbrookes Hospital

    Cambridge, United Kingdom · Recruiting

  • Velindre Cancer Centre

    Cardiff, United Kingdom · Recruiting

  • Broomfield Hospital

    Chelmsford, United Kingdom · Recruiting

  • Cheltenham General Hospital

    Cheltenham, United Kingdom · Recruiting

  • Colchester General Hospital

    Colchester, United Kingdom · Recruiting

  • University Hospital Coventry & Warwickshire

    Coventry, United Kingdom · Recruiting

  • Western General Hospital

    Edinburgh, United Kingdom · Recruiting

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom · Recruiting

  • Diana Princess of Wales Hospital

    Grimsby, United Kingdom · Recruiting

  • Castle Hill Hospital

    Hull, United Kingdom · Recruiting

  • Raigmore Hospital

    Inverness, United Kingdom · Recruiting

  • St James University Hospital

    Leeds, United Kingdom · Recruiting

  • Leicester Royal Infirmary

    Leicester, United Kingdom · Recruiting

  • Clatterbridge Cancer Centre

    Liverpool, United Kingdom · Recruiting

  • St Bartholomew's Hospital

    London, United Kingdom · Recruiting

  • Mount Vernon Hospital

    London, United Kingdom · Recruiting

  • Royal Free Hospital

    London, United Kingdom · Recruiting

  • Guy's Hospital

    London, United Kingdom · Recruiting

  • Royal Marsden Hospital

    London, United Kingdom · Recruiting

  • Charing Cross Hospital

    London, United Kingdom · Recruiting

  • The Christie

    Manchester, United Kingdom · Recruiting

  • Nottingham University Hospital

    Nottingham, United Kingdom · Recruiting

  • Churchill Hospital

    Oxford, United Kingdom · Recruiting

  • Glan Clwyd Hospital

    Rhyl, United Kingdom · Recruiting

  • Scunthorpe General Hospital

    Scunthorpe, United Kingdom · Recruiting

  • Weston Park Hospital

    Sheffield, United Kingdom · Recruiting

  • South Tyneside District Hospital

    South Shields, United Kingdom · Recruiting

  • Southend University Hospital

    Southend-on-Sea, United Kingdom · Recruiting

  • Sunderland Royal Hospital

    Sunderland, United Kingdom · Recruiting

  • Royal Marsden Hospital

    Sutton, United Kingdom · Recruiting

  • Torbay Hospital

    Torquay, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.